Zoetis Inc.

Zoetis Inc.

ZTSยทNYSE

$77.59

+0.039%
HealthcareDrug Manufacturers - General

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

At a Glance

Live Snapshot
Market Cap$32.53B
EPS6.0300
P/E Ratio12.87
Earnings Date08/04/2026
3Y+17.0%
5Y+42.0%
10Y+94.0%
3Y+26.0%
5Y+63.0%
10Y+226.0%
3Y+52.0%
5Y+37.0%
10Y+307.0%
Zoetis Inc.

Zoetis Inc. Profit Bridge

ZTS ยท NYSE
Revenue9.47B
Cost of Goods Sold (2.79B)
Gross Profit6.67B
Operating Expenses (3.08B)
Operating Income3.60B
Interest Expense (243.00M)
Other Income/Expense-237.00M
Pretax Income3.36B
Income Tax (687.00M)
Net Income2.67B
Net Income
2.67B

Profitability Analysis

Gross Margin

70.5%

Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.

Operating Margin

38.0%

Outstanding operational efficiency. The company generates substantial profit from core operations.

Net Profit Margin

28.2%

Exceptional profitability. The company converts a significant portion of revenue to bottom-line earnings.

Effective Tax Rate

20.4%

Moderate tax rate typical for most corporations. Represents standard tax burden on profits.

Profitability Insight

Exceptional profitability across all levels: Strong pricing power, efficient operations, and healthy bottom line indicate a high-quality business with sustainable competitive advantages.

Zoetis Inc. Income Statement

ZTS โ€ข NYSE

Zoetis Inc. Income StatementDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015Dec 2014Dec 2013Dec 2012Dec 2011Dec 2010Dec 2009
REVENUE
9.5B
9.3B
8.5B
8.1B
7.8B
6.7B
6.3B
5.8B
5.3B
4.9B
4.8B
4.8B
4.6B
4.3B
4.2B
3.6B
2.8B
GROSS PROFIT
(2.8B)
(2.9B)
(2.7B)
(2.6B)
(2.5B)
(2.2B)
(2.1B)
(2B)
(1.9B)
(1.7B)
(1.8B)
(1.8B)
(1.7B)
(1.6B)
(1.7B)
(1.5B)
(1.1B)
6.7B
6.4B
5.8B
5.5B
5.3B
4.5B
4.1B
3.8B
3.4B
3.1B
3B
3B
2.8B
2.7B
2.5B
2.1B
1.7B
OPERATING INCOME
(3.1B)
(3B)
(2.8B)
(2.5B)
(2.5B)
(2.2B)
(2.1B)
(1.9B)
(1.7B)
(1.7B)
(1.9B)
(2B)
(2B)
(1.9B)
(1.9B)
(1.8B)
(1.4B)
(2.4B)
(2.3B)
(2.2B)
(2B)
(2B)
(1.7B)
(1.6B)
(1.5B)
(1.3B)
(1.3B)
(1.4B)
(1.5B)
(1.4B)
(1.5B)
(1.5B)
(1.4B)
(1.1B)
(698M)
(686M)
(614M)
(539M)
(508M)
(463M)
(457M)
(432M)
(382M)
(376M)
(364M)
(396M)
(399M)
(409M)
(427M)
(411M)
(368M)
3.6B
3.4B
3.1B
2.9B
2.8B
2.3B
2B
1.9B
1.7B
1.4B
1.1B
970M
821M
854M
684M
309M
281M
PRE-TAX INCOME
(243M)
(242M)
(258M)
(237M)
(236M)
(249M)
(242M)
(212M)
(175M)
(166M)
(124M)
(117M)
(113M)
(31M)
(36M)
(37M)
(26M)
-150M
-136M
-153M
-187M
-230M
-237M
-205M
-181M
-175M
-166M
-124M
-117M
-113M
-31M
-36M
-37M
-26M
-237M
-259M
-133M
-272M
-315M
-273M
-217M
-191M
-202M
-176M
-537M
-150M
-133M
-144M
-290M
-131M
-429M
3.4B
3.1B
2.9B
2.7B
2.5B
2B
1.8B
1.7B
1.5B
1.2B
545M
820M
690M
710M
394M
178M
-148M
NET INCOME
(687M)
(637M)
(596M)
(545M)
(454M)
(360M)
(301M)
(266M)
(663M)
(409M)
(206M)
(233M)
(187M)
(274M)
(146M)
(67M)
-47M
2.7B
2.5B
2.3B
2.1B
2B
1.6B
1.5B
1.4B
864M
821M
339M
583M
504M
436M
245M
110M
-100M

SEC Filings

ZTS - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
8-K

8-K 2026

N/A

May 22, 2026
May 20, 2026
2026
8-K

8-K 2026

N/A

May 20, 2026
May 20, 2026
2026
10-Q

10-Q 2026 Q1

Q1

May 07, 2026
March 31, 2026
2026
8-K

8-K 2026

N/A

May 07, 2026
May 07, 2026
2026
DEF 14A

DEF 14A 2025

N/A

April 08, 2026
December 31, 2025
2025
10-K

10-K 2025 FY

FY

February 12, 2026
December 31, 2025
2025
8-K

8-K 2026

N/A

February 12, 2026
February 12, 2026
2026
8-K

8-K 2026

N/A

February 05, 2026
February 05, 2026
2026
8-K

8-K 2025

N/A

December 18, 2025
December 15, 2025
2025
8-K

8-K 2025

N/A

December 11, 2025
December 11, 2025
2025
Showing 1 to 10 of 258 filings